ReachMD

Be part of the knowledge.™

Oncology - Hematology

75

LikeLikedUnlike

Episodes 1-15 of 29

- Jennifer Caudle, DO
  Peer
- Fernando Uriel Garcia, MD
  Peer
2
Medical Industry Feature
A Pathologist’s Perspective: The Role of Biomarker Testing in Metastatic Colorectal Cancer
A Pathologist’s Perspective: The Role of Biomarker Testing in Metastatic Colorectal Cancer
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Nicole Lamanna, MD
  Peer
0
Medical Industry Feature
What to Know About a Treatment Option That Targets BCL2
What to Know About a Treatment Option That Targets BCL2
- Jennifer Caudle, DO
  Peer
- Coy Heldermon, MD, PhD
  Peer
- Heather Lau, MD, MS
  Peer
7
Medical Industry Feature
How Can We Prevent the Delayed Diagnosis of Type 1 Gaucher Disease?
How Can We Prevent the Delayed Diagnosis of Type 1 Gaucher Disease?
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Harry Paul Erba, MD, PhD
  Peer
- Uma Borate, MD, MS
  Peer
1
Medical Industry Feature
Advances in AML: The Role of a Targeted Therapy in Current Treatment Paradigms
Advances in AML: The Role of a Targeted Therapy in Current Treatment Paradigms
- Jennifer Caudle, DO
  Peer
- Keith McCrae, MD
  Peer
- Terry B. Gernsheimer, MD
  Peer
1
Medical Industry Feature
Immune Thrombocytopenia: Updated Practice Guidelines in an Evolving Treatment Landscape
Immune Thrombocytopenia: Updated Practice Guidelines in an Evolving Treatment Landscape
- John J. Russell, MD
  Peer
- Fernando de Zarraga, MD
  Peer
- Raed Al-Rajabi, MD
  Peer
3
$Exploring an Evidence-Based Treatment Pathway for Chemorefractory Wild-Type RAS Metastatic Colorectal Cancer$ $Exploring an Evidence-Based Treatment Pathway for Chemorefractory Wild-Type RAS Metastatic Colorectal Cancer$
Medical Industry Feature
Exploring an Evidence-Based Treatment Pathway for Chemorefractory Wild-Type RAS Metastatic Colorectal Cancer
Exploring an Evidence-Based Treatment Pathway for Chemorefractory Wild-Type RAS Metastatic Colorectal Cancer
- Matt Birnholz, MD
  Peer
- Ralph V. Boccia, MD
  Peer
- James Bussel, MD
  Peer
2
Medical Industry Feature
Expert Perspectives on Immune Thrombocytopenia
Expert Perspectives on Immune Thrombocytopenia
- Jennifer Caudle, DO
  Peer
- Suma Satti, MD
  Peer
7
Medical Industry Feature
Exploring First-Line Treatment in Extensive-Stage Small Cell Lung Cancer
Exploring First-Line Treatment in Extensive-Stage Small Cell Lung Cancer
- Ilene Galinsky BSN,MSN,ANP-C
  Peer
1
Medical Industry Feature
Monitoring for Neutropenia in Acute Myeloid Leukemia
Monitoring for Neutropenia in Acute Myeloid Leukemia
- Ilene Galinsky BSN,MSN,ANP-C
  Peer
3
Medical Industry Feature
The Ramp-Up & Dosing of an Acute Myeloid Leukemia Therapy
The Ramp-Up & Dosing of an Acute Myeloid Leukemia Therapy
- Matthew S. Davids, MD, MMSc
  Peer
- Andrew Souers, PhD
  Peer
2
Medical Industry Feature
When Apoptosis Becomes Impaired: Targeting BCL-2
When Apoptosis Becomes Impaired: Targeting BCL-2
- Paul Doghramji, MD
  Peer
- Alex Spira, MD, PhD, FACP
  Peer
- John Longshore, PhD, FACMG
  Peer
2
Medical Industry Feature
Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape
Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape
1
Medical Industry Feature
Impact of Hemoglobin S Polymerization on Sickle Cell Disease
Impact of Hemoglobin S Polymerization on Sickle Cell Disease
- Ken H. Shain, MD, PhD
  Peer
0
$The Role of a Triplet Regimen in Relapsed/Refractory Multiple Myeloma$ $The Role of a Triplet Regimen in Relapsed/Refractory Multiple Myeloma$
Medical Industry Feature
The Role of a Triplet Regimen in Relapsed/Refractory Multiple Myeloma
The Role of a Triplet Regimen in Relapsed/Refractory Multiple Myeloma
- Harry Paul Erba, MD, PhD
  Peer
1
Medical Industry Feature
Therapeutic Targets in Acute Myeloid Leukemia
Therapeutic Targets in Acute Myeloid Leukemia

Programs 4/20/21

Segment Chapters

Playlist:

Recommended